Clinical Benefit of Empiric High-dose Levofloxacin Therapy for Adults With Community-onset Enterobacteriaceae Bacteremia.

Clinical Benefit of Empiric High-dose Levofloxacin Therapy for Adults With Community-onset Enterobacteriaceae Bacteremia. Clin Ther. 2019 Aug 15;: Authors: Lee CC, Yang CY, Lee CH, Hsieh CC, Hong MY, Tang HJ, Ko WC Abstract PURPOSE: Levofloxacin is commonly prescribed to treat varied community-acquired gram-negative infections; knowledge of the therapeutic efficacies of high-dose (HD) administration is helpful to improve patient care. METHODS: In this 6-year cohort, adults with community-onset Enterobacteriaceae bacteremia were retrospectively studied in 2 hospitals. To overcome the confounding factors in the dosage choice of empiric administration, patients receiving empiric intravenous HD (750 mg/d) therapy were matched with those receiving the conventional dose (CD; 500 mg/d) by using individual propensity scores, calculated by the independent predictors of 30-day crude mortality. FINDINGS: Initially, more patients with critical illness (Pitt bacteremia score [PBS] ≥4) at bacteremia onset and comorbid malignancies and the higher 15- and 30-day mortality rate were recorded in 136 patients receiving HD therapy, compared to 103 receiving CD therapy. After appropriate matching, differences in patient demographic and clinical characteristics between the HD (n = 103) and CD (n = 103) groups were nonsignificant. Consequently, crude mortality rates at 3, 15, or 30 days after onset of bacteremia did not differ. Howe...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research